| Project Detail |
The project is a long-term investment program to develop, manufacture and commercialize additional biosimilar monoclonal antibodies targeting oncology and autoimmunity-based diseases, which is a highly unmet medical need in Africa. With the objective of building a biological Active Pharmaceutical Ingredients (API) hub to serve Africa and the Middle East (MEA) region, the investment program includes: (i) product development, construction, and the equipping of a second drug substance and drug product biotechnology facility in Cairo, Egypt (“XpandC”) and (ii) renovation of existing production lines. |
